Loading...
NPI 1295862134 · Fredericksburg, VA · Hematology & Oncology Physician
Customize your policy alerts
Get alerted when relevant policies change without checking for updates manually.
Monitor payer policy activity
Manan Mehta is a hematology & oncology physician provider located in Fredericksburg, Virginia. This profile covers 34 Medicare and 9 Medicaid CPT/HCPCS procedure codes, with claims volume, average reimbursement, and total revenue by code, benchmarked against other providers billing the same services.
Provider details (source: NPPES NPI Registry)
| Field | Value |
|---|---|
| Entity Type | Individual |
| Organization | Manan Mehta |
| Address | 405 Chatham Heights Rd |
| City | Fredericksburg |
| State | VA |
| ZIP | 22405 |
| Taxonomy | Hematology & Oncology Physician |
| NPI Enumerated | February 27, 2007 |
Lifetime revenue by payer source (source: CMS Medicare & Medicaid claims data)
| Payer Source | Total Paid |
|---|---|
| Medicare | $1.5M |
| Medicaid | $0 |
Medicare revenue breakdown by CPT/HCPCS procedure code.
View: Bar Chart1 / 2
The CPT/HCPCS codes generating the most Medicare revenue for this provider.
34 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| J9271 | Injection, pembrolizumab, 1 mg | 16,800 | $40 | $722.5K |
| J0129 | Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | 6,350 | $30 | $209.6K |
| J0897 | Injection, denosumab, 1 mg | 7,980 | $20 | $143.7K |
| Q5104 | Injection, infliximab-abda, biosimilar, (renflexis), 10 mg | 3,810 | $30 | $110.5K |
| 99213 | The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a low level of medical decision making, and/or the… | 880 | $70 | $58.8K |
| 96413 | Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These… | 470 | $100 | $47.1K |
| 96367 | The provider administers an additional intravenous infusion or infusions, after an initial infusion, of a different medication or substance for a period up to one hour to prevent, treat, or diagnose… | 2,050 | $20 | $45K |
| 99215 | The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a high level of medical decision making, and/or the… | 280 | $130 | $37K |
| 99214 | The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the… | 340 | $100 | $32.3K |
| Q5122 | Injection, pegfilgrastim-apgf (nyvepria), biosimilar, 0.5 mg | 260 | $110 | $27.3K |
Showing 1–10 of 34
How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 34 CPT/HCPCS codes.
View: State1 / 2
Full comparison — all codes billed, vs. state median
34 rows
| CPT/HCPCS Code | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|
| J9271 | 28 | 110 | 12,800 | $40 | $610.9K |
| J0129 | 27 | 30 | 10,450 | $30 | $407.3K |
| J0897 | 54 | 340 | 2,820 | $20 | $89.3K |
| Q5104 | 1 | 10 | 1,390 | $30 | $53.5K |
| Q5122 | 23 | 40 | 270 | $90 | $32.5K |
| 96413 | 35 | 230 | 250 | $100 | $28.5K |
| 99214 | 3,243 | 12,890 | 140 | $80 | $21K |
| J3490 | 1 | 110 | 60 | $280 | $20.5K |
| J0885 | 15 | 40 | 2,610 | $10 | $17.3K |
| 99232 | 2,212 | 4,460 | 80 | $60 | $11K |
Showing 1–10 of 34
Medicaid revenue breakdown by year and by CPT/HCPCS procedure code, including monthly billing trends and the top codes driving revenue.
View: By Year1 / 3
Every CPT/HCPCS code this provider has billed to Medicaid, with claims volume, average payment, and total revenue.
9 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| 1123F | No Summary found for this code | 270 | $0 | $0 |
| 4004F | The provider screens a patient of 18 years of age or older for the use of tobacco. If he identifies the patient as a tobacco user, the provider offers cessation counseling or drugs or a combination… | 210 | $0 | $0 |
| G8420 | Bmi is documented within normal parameters and no follow-up plan is required | 210 | $0 | $0 |
| G8427 | Eligible clinician attests to documenting in the medical record they obtained, updated, or reviewed the patient's current medications | 270 | $0 | $0 |
| G8510 | Screening for depression is documented as negative, a follow-up plan is not required | 210 | $0 | $0 |
| G8752 | Most recent systolic blood pressure < 140 mmhg | 210 | $0 | $0 |
| G8754 | Most recent diastolic blood pressure < 90 mmhg | 210 | $0 | $0 |
| G9621 | Patient identified as an unhealthy alcohol user when screened for unhealthy alcohol use using a systematic screening method and received brief counseling | 50 | $0 | $0 |
| G9622 | Patient not identified as an unhealthy alcohol user when screened for unhealthy alcohol use using a systematic screening method | 100 | $0 | $0 |
How this provider's Medicaid billing volume and revenue compare to other Virginia providers billing the same CPT/HCPCS codes.
Full comparison — all codes billed, vs. Virginia median
9 rows
| CPT/HCPCS Code | Description | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|---|
| 1123F | No Summary found for this code | 16 | 60 | 80 | $1 | $3.3K |
| G8427 | Eligible clinician attests to documenting in the medical record they obtained, updated, or reviewed the patient's current medications | 146 | 310 | 220 | $1 | $1.1K |
| 4004F | The provider screens a patient of 18 years of age or older for the use of tobacco. If he identifies the patient as a tobacco user, the provider offers cessation counseling or drugs or a combination… | 17 | 50 | 100 | $1 | $190 |
| G8510 | Screening for depression is documented as negative, a follow-up plan is not required | 62 | 120 | 230 | $1 | $40 |
| G8420 | Bmi is documented within normal parameters and no follow-up plan is required | 16 | 50 | 100 | $1 | $10 |
| G8752 | Most recent systolic blood pressure < 140 mmhg | 34 | 90 | 100 | $1 | $1 |
| G8754 | Most recent diastolic blood pressure < 90 mmhg | 47 | 110 | 100 | $1 | $1 |
| G9621 | Patient identified as an unhealthy alcohol user when screened for unhealthy alcohol use using a systematic screening method and received brief counseling | 2 | 10 | 390 | $0 | $0 |
| G9622 | Patient not identified as an unhealthy alcohol user when screened for unhealthy alcohol use using a systematic screening method | 5 | 10 | 100 | $0 | $0 |
Other providers in the same ZIP code as Manan Mehta, ranked by combined Medicare and Medicaid revenue.
| Provider | State | Taxonomy | Medicare Revenue | Medicaid Revenue |
|---|---|---|---|---|
| Addus Healthcare, Inc. | VA | In Home Supportive Care Agency | $0 | $9.9M |
| Devashish Sen | VA | Physical Medicine & Rehabilitation Physician | $717.7K | $0 |
| Arash Mansouri | VA | Ophthalmology Physician | $518.4K | $19.9K |
| Philip Brandt | VA | Hematology & Oncology Physician | $460.5K | $0 |
| Matthew Tadrus | VA | Ophthalmology Physician | $389.2K | $0 |
| Steven Hudson | VA | Ophthalmology Physician | $278.2K | $0 |
| Anusha Manje Gowda | VA | Hematology & Oncology Physician | $134.5K | $0 |
| Darrell Dila | VA | Physical Therapist | $134.1K | $0 |
| Angela Tsai | VA | Optometrist | $104.5K | $0 |
| Laboratory Corporation Of America Holdings | VA | Clinical Medical Laboratory | $45.3K | $24.2K |
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.